A comprehensive overview of the genetic counseling process, predictive and presymptomatic testing, pediatric considerations, reproductive options, and ethical frameworks — with emphasis on neurogenetic conditions and clinical decision-making.
Tags: Neurogenetics
Genetic counseling is a communication process that helps individuals and families understand and adapt to the medical, psychological, and familial implications of genetic contributions to disease. The process is guided by the principle of non-directiveness — the counselor provides balanced, complete information and supports autonomous decision-making without steering the patient toward a particular choice. Pre-test counseling is the foundation. It begins with construction of a three-generation pedigree to identify inheritance patterns, affected relatives, consanguinity, and ethnic background relevant to carrier frequencies. Risk assessment follows, integrating the pedigree data with the patient's clinical presentation to estimate the probability of a genetic diagnosis. The counselor then discusses test selection — which assay is most appropriate (gene panel, exome, genome, repeat expansion testing) — and the range of possible outcomes. Critically, patients must understand that testing may yield not only a definitive diagnosis but also variants of uncertain significance (VUS), incidental or secondary findings (such as ACMG v3.2 medically actionable genes), and in rare cases, unexpected findings such as non-paternity or consanguinity. Informed consent must be documented and should address the purpose of testing, the types of results that may be returned, limitations of the test (sensitivity, conditions not covered), implications for family members, potential insurance or psychosocial consequences, and the option to decline testing entirely. Shared decision-making ensures that patient values and preferences are central to the testing plan. Post-test counseling involves result disclosure in a supportive setting, interpretation of findings in the context of the patient's phenotype, psychosocial support (including referral to mental health professionals when needed), and coordination with specialists for management. For negative or uninformative results, the counselor discusses residual risk and the possibility of future re-analysis as genomic knowledge evolves.
Key Points
Predictive (presymptomatic) testing identifies whether an at-risk individual who is currently healthy carries a pathogenic variant that will or may cause disease in the future. This type of testing carries profound psychological, social, and legal implications and requires a rigorous counseling framework. Huntington disease (HD) is the paradigm for predictive testing. Because HD is autosomal dominant with near-complete penetrance (CAG ≥40 repeats) and no disease-modifying treatment currently exists, a positive result effectively tells a healthy person they will develop a devastating neurodegenerative disease. The international HD predictive testing protocol, originally developed by the International Huntington Association and the World Federation of Neurology in 1994, requires a minimum of two pre-test counseling sessions separated by a cooling-off period, a psychological assessment to screen for depression and suicidality, the presence of an identified support person, and explicit discussion of the impact on partners, children, and employment. Testing of minors is not performed unless a medical intervention exists for the childhood-onset form. The protocol also specifies that results should never be disclosed by telephone or to third parties without the patient's explicit consent. Analogous considerations apply to predictive testing for other adult-onset conditions such as BRCA1/2-associated cancer syndromes and Lynch syndrome, though in those cases the availability of risk-reducing interventions (surveillance, prophylactic surgery) shifts the risk-benefit balance toward testing. The right not to know is a recognized ethical principle. At-risk individuals are never obligated to undergo predictive testing, and family members must not pressure or coerce testing. In families with HD, testing a grandchild can inadvertently reveal the status of an intervening parent who has chosen not to know — a situation requiring careful counseling and sometimes the use of exclusion testing (linkage-based) to preserve the parent's right not to know. Insurance implications vary by jurisdiction. In the United States, the Genetic Information Nondiscrimination Act (GINA, 2008) prohibits discrimination by health insurers and employers based on genetic information. However, GINA does NOT protect against discrimination in life insurance, disability insurance, or long-term care insurance. This gap means that a positive predictive test result for HD can legally be used to deny life insurance coverage. Patients must be counseled about these limitations before testing. Some individuals choose to secure life and disability insurance policies before undergoing predictive testing. The psychological impact of predictive testing is significant. Studies of HD predictive testing show that approximately 10% of individuals experience clinically significant adverse psychological reactions (depression, anxiety, relationship disruption), with the highest risk in the first year after a positive result. Paradoxically, some individuals who receive negative results also experience psychological distress, including survivor guilt and identity disruption.
Key Points
Genetic testing in children requires balancing the potential medical benefit of early diagnosis against the child's future autonomy — their right to make their own informed decisions about genetic testing as adults. Testing is widely accepted and recommended when results will lead to childhood-onset medical interventions that improve outcomes. Examples include tuberous sclerosis complex (TSC), where identification of a TSC1 or TSC2 pathogenic variant triggers a surveillance protocol (brain MRI, renal ultrasound, echocardiography, ophthalmologic exam) that enables early detection and treatment of subependymal giant cell astrocytomas, renal angiomyolipomas, and cardiac rhabdomyomas. Similarly, spinal muscular atrophy (SMA) now has disease-modifying therapies (nusinersen, onasemnogene abeparvovec, risdiplam) whose efficacy is dramatically greater when initiated presymptomatically — making early genetic identification medically actionable and time-sensitive. Testing minors for adult-onset conditions without childhood medical actionability is controversial and generally discouraged. The classic example is HD: testing a child for the HD CAG expansion when there is no childhood intervention removes the child's future right to make an autonomous decision about whether to know their status. The ACMG and the American Academy of Pediatrics (AAP) jointly recommend deferring predictive testing for adult-onset conditions until the individual is mature enough to provide informed consent, typically at age 18. Exceptions may be considered when a mature minor demonstrates clear understanding and requests testing, but these situations require careful ethical deliberation. Newborn screening (NBS) is a public health program that identifies presymptomatic infants with conditions for which early treatment improves outcomes. In the United States, the Recommended Uniform Screening Panel (RUSP) determines which conditions are included. SMA was added to the RUSP in 2018, a landmark decision driven by the availability of gene therapy and antisense oligonucleotide treatments. As of 2024, all 50 US states screen for SMA. The expanding NBS panel raises questions about the appropriate threshold for inclusion — should conditions with variable expressivity, incomplete penetrance, or treatments of uncertain long-term efficacy be added? Genome-wide newborn screening (gNBS) is under active investigation through pilot programs such as BabySeq, Guardian, and the UK Genomics England Newborn Genomes Programme. Potential benefits include detection of hundreds of treatable conditions. Concerns include the generation of large numbers of VUS, identification of adult-onset conditions (violating the child's future autonomy), parental anxiety from uncertain results, and the "patient-in-waiting" phenomenon — where a child identified with a genetic predisposition is treated as pre-symptomatic rather than healthy, potentially affecting family dynamics, self-identity, and even access to insurance.
Key Points
Families affected by heritable neurogenetic conditions have a range of reproductive options. Genetic counseling before conception allows couples to understand their risks and make informed decisions aligned with their values. Carrier screening identifies healthy individuals who carry one copy of a recessive pathogenic variant. The American College of Obstetricians and Gynecologists (ACOG) now recommends that all patients who are pregnant or considering pregnancy be offered expanded carrier screening panels, which typically cover 100–400+ genes regardless of ethnicity. This pan-ethnic approach has replaced the older ethnicity-based screening model. For neurogenetic conditions, expanded panels include SMA (SMN1 copy number), Tay-Sachs disease, Canavan disease, fragile X premutation carrier status, and many others. When both partners are identified as carriers of the same autosomal recessive condition (or when one partner carries an autosomal dominant or X-linked variant), prenatal diagnostic options include chorionic villus sampling (CVS) at 10–13 weeks' gestation and amniocentesis at 15–20 weeks. Both procedures carry a small procedure-related miscarriage risk (approximately 0.1–0.3%) and provide definitive genetic diagnosis of the fetus. Preimplantation genetic testing for monogenic disorders (PGT-M) is an alternative that avoids the need for decisions about pregnancy termination. In PGT-M, embryos created through in vitro fertilization (IVF) are biopsied at the blastocyst stage, and only unaffected embryos are transferred. PGT-M requires prior identification of the familial variant, a custom probe development period (typically 4–6 weeks), and the physical, emotional, and financial demands of IVF. PGT-M is available for virtually any monogenic neurogenetic condition with a known pathogenic variant, including HD, SMA, TSC, and SCN1A-related epilepsies. Non-invasive prenatal screening (NIPS), also called cell-free DNA (cfDNA) screening, analyzes fetal DNA fragments circulating in maternal blood. NIPS is highly accurate for common aneuploidies (trisomy 21, 18, 13) but is increasingly marketed for microdeletion syndromes such as 22q11.2 deletion. For rare microdeletion conditions, NIPS has a high false positive rate due to low positive predictive value in a low-prevalence population — a positive NIPS result for a rare condition requires confirmatory diagnostic testing (CVS or amniocentesis) before clinical action. Reproductive autonomy — the right to make one's own reproductive decisions free of coercion — is a cornerstone ethical principle. Disability rights perspectives challenge the assumption that preventing the birth of a child with a genetic condition is inherently desirable, emphasizing the value and dignity of disabled lives and the social model of disability. Genetic counselors must present information in a balanced, non-directive manner that respects diverse perspectives. Additional options include use of donor gametes (egg or sperm from an unaffected donor), embryo donation, and adoption. Each carries its own emotional, ethical, legal, and financial considerations that should be explored in counseling.
Key Points
The rapidly expanding scope of genomic medicine in neurogenetics raises ethical questions that outpace existing guidelines. Several key areas demand ongoing attention from clinicians, counselors, and policymakers. Duty to recontact and variant reclassification: As genomic knowledge evolves, variants initially classified as VUS may be reclassified to pathogenic or benign. This raises the question of whether laboratories and clinicians have an obligation to recontact patients when reclassification occurs. Current practice varies: some laboratories issue amended reports, while others rely on clinicians to request periodic re-analysis. Professional societies (ACMG, ESHG) have discussed but not mandated a universal duty to recontact, citing logistical challenges and resource constraints. Best practice encourages systematic re-analysis workflows and clear communication to patients at the time of initial testing that reclassification may occur. Data sharing and genomic databases: Variant classification accuracy depends on aggregated data. Databases like ClinVar (public variant-level assertions from clinical laboratories) and DECIPHER (phenotype-linked copy number and sequence variants) improve classification by enabling comparison across patients worldwide. Contributing clinical data to these resources is ethically supported by the principle of beneficence — sharing data helps future patients. However, privacy considerations require de-identification, and patients should be informed during consent that their de-identified genetic data may be shared in research databases. Direct-to-consumer (DTC) genetic testing: Companies such as 23andMe offer health-related genetic reports directly to consumers. The FDA has authorized 23andMe to report APOE ε4 status (Alzheimer disease risk) and three specific BRCA1/BRCA2 founder mutations. Limitations are significant: DTC tests screen only selected variants, not the full gene, so a negative result does NOT rule out pathogenic variants. Consumers frequently misinterpret results — a negative BRCA DTC result may provide false reassurance to someone with a strong family history who actually carries a different pathogenic BRCA variant. The APOE ε4 result provides relative risk information for a multifactorial condition and requires careful contextual interpretation. DTC results should always be confirmed by clinical-grade testing before medical decisions are made. Equity and access: There is a critical shortage of genetic counselors, particularly in rural and underserved communities. As of 2024, there are approximately 6,000 certified genetic counselors in the United States, far below the estimated need. Telegenetics — the delivery of genetic counseling services via telemedicine — has expanded access significantly, especially following the COVID-19 pandemic, but disparities persist. Minority and underrepresented populations are underrepresented in genomic databases (gnomAD, ClinVar), which can lead to higher VUS rates and diagnostic inequity. Cultural considerations, including varying beliefs about genetic determinism, disability, and reproductive decision-making, must be integrated into counseling practice. Emerging frontiers: Fetal whole genome sequencing is technically feasible but raises questions about the return of results for adult-onset conditions and incidental findings in a fetus. Polygenic risk scores (PRS) for neuropsychiatric conditions (schizophrenia, autism spectrum disorder, Alzheimer disease) are being developed but currently have limited clinical utility — they explain only a fraction of disease risk, perform poorly across ancestries, and risk exacerbating genetic determinism and stigma. Somatic gene editing (e.g., CRISPR-based therapies for sickle cell disease) is now clinically approved, but germline gene editing — altering the DNA of embryos in ways that would be inherited by future generations — remains ethically contentious and is prohibited in most jurisdictions. The 2018 He Jiankui affair, in which CRISPR was used to edit human embryos, was widely condemned and resulted in criminal prosecution.
Key Points
1. A clinical exome sequencing report identifies a variant of uncertain significance (VUS) in KCNQ2 in a 3-month-old infant with neonatal-onset epilepsy. The infant's seizures are well controlled on carbamazepine. During counseling, the parents ask whether this VUS confirms their child's diagnosis. What is the most appropriate counseling approach?
A VUS cannot be used to confirm a clinical diagnosis. The appropriate approach is to explain that current evidence is insufficient to determine pathogenicity, recommend segregation testing in parents (which can generate PP1 or PS2 evidence), and plan for re-analysis in 1-2 years as databases and functional knowledge grow. Treatment decisions should be guided by the clinical picture, not the VUS — so carbamazepine should be continued if clinically effective. Clinicians cannot unilaterally reclassify variants without additional evidence meeting ACMG criteria.
2. A 28-year-old woman whose father died of Huntington disease requests predictive testing. She has no neurological symptoms. According to the international HD predictive testing protocol, which of the following is required before testing can proceed?
The international HD predictive testing protocol requires a minimum of two pre-test counseling sessions separated by a cooling-off period, a psychological assessment to screen for depression and suicidality, and identification of a support person. Brain MRI is not part of the protocol, sibling testing is not required, and the familial diagnosis is confirmed through review of medical records — not a letter from the treating neurologist.
3. The parents of a healthy 5-year-old boy with a family history of Huntington disease (affected grandfather) request predictive HD testing for their son. What is the most appropriate response?
ACMG and AAP guidelines recommend deferring predictive testing for adult-onset conditions without childhood medical actionability until the individual is mature enough to provide informed consent (typically age 18). Testing this child for HD would remove his future right to decide whether he wants to know his status. Parental consent authority does not override this ethical principle. Exclusion testing is a technique used to protect an intervening parent's right not to know, not applicable in this scenario for the child.
4. A couple in which the mother is a carrier of an SMN1 deletion (SMA carrier) and the father is also confirmed as a carrier seeks counseling about reproductive options. They wish to avoid prenatal diagnosis with possible termination. Which option best addresses their preference?
PGT-M (preimplantation genetic testing for monogenic disorders) combined with IVF allows embryos to be tested for the familial SMN1 deletions at the blastocyst stage, with only unaffected or carrier embryos transferred. This directly addresses the couple's preference to avoid prenatal diagnosis and potential termination. NIPS does not currently screen for SMA and is a screening (not diagnostic) tool. Adoption eliminates genetic risk but was not what the couple requested. Rescreening does not change their confirmed carrier status.
5. A clinical genetics laboratory reclassifies a previously reported VUS in TSC2 to likely pathogenic based on new functional data and additional affected individuals in ClinVar. The patient was tested 3 years ago. What is the current best practice regarding recontacting the patient?
The duty to recontact when variants are reclassified is ethically supported by principles of beneficence — in this case, a reclassification from VUS to likely pathogenic in TSC2 could trigger surveillance for renal, cardiac, and CNS complications that significantly impact patient care. Current best practice encourages laboratories to issue amended reports and for clinicians to establish re-analysis workflows. However, a universal legally mandated duty to recontact has not been established by professional societies (ACMG, ESHG), primarily due to logistical and resource challenges. GINA does not address recontact obligations.
6. A 35-year-old man undergoes presymptomatic genetic testing for a familial neurogenetic condition and receives a positive result. He subsequently applies for a new life insurance policy. Under the Genetic Information Nondiscrimination Act (GINA) in the United States, which of the following is true?
GINA (Genetic Information Nondiscrimination Act, 2008) prohibits discrimination based on genetic information by health insurers (Title I) and employers (Title II). However, GINA does NOT extend protections to life insurance, disability insurance, or long-term care insurance. This is a critical gap that patients must be informed about during pre-test counseling, as a positive presymptomatic result can legally be used to deny life insurance coverage.